The failure of biological treatment in axial spondyloarthritis is linked to the factors related to increased intestinal permeability and dysbiosis: prospective observational cohort study
Open Access
- 14 May 2024
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 44 (8) , 1487-1499
Abstract
Background: A significant number of patients with axial spondyloarthritis (axSpA) do not respond to biological therapy. Therefore, we decided to investigate the specificity of this group of patients and, in particular, whether haptoglobin (Hp), its polymorphism and zonulin, in addition to other clinical features, are predictors of poor response to biological treatment. Methods: 48 patients with axSpA who were unsuccessfully treated with standard drugs were converted to biological treatment, and from this time on, a 12-week follow-up was started to assess the failure of biological treatment (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) decrease < 2 points). Predictors of treatment failure were identified using logistic regression analysis. Results: 21% of subjects had biological treatment failure. Patients who had a higher zonulin level, a history of frequent infections, were older, had inflammatory bowel disease (IBD), had a lower Hp level at the time of inclusion in biological therapy showed an increased risk of treatment failure. Conclusions: The results of the study support the hypothesis that the effectiveness of biological treatment of axSpA is limited by changed microbiota and intestinal epithelial barrier dysfunction, as an increased risk of biological treatment failure was observed in patients who were older, had higher zonulin level, IBD and repeated courses of antibiotics due to frequent infections. Therefore, starting biological treatment should be followed by reducing intestinal permeability and regulating the disturbed gut microbiome.Keywords
This publication has 49 references indexed in Scilit:
- Predictors of treatment failure of non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis with focus on haptoglobin, haptoglobin polymorphism and zonulinRheumatology International, 2023
- Effect of Biologics in Subgroups of Axial Spondyloarthritis Based on Magnetic Resonance Imaging and C‐Reactive Protein: A Systematic Review and Meta‐AnalysisACR Open Rheumatology, 2023
- Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationSeminars in Arthritis and Rheumatism, 2022
- Predictors of remission in people with axial spondyloarthritis: A systematic literature reviewSeminars in Arthritis and Rheumatism, 2022
- Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized DefinitionAdvances in Therapy, 2022
- The aging gut microbiome and its impact on host immunityGenes & Immunity, 2021
- Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular OutcomesJACC, 2020
- Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to TreatmentClinical Drug Investigation, 2019
- Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial SpondyloarthritisArthritis Care & Research, 2018
- Haptoglobin Polymorphisms Are Associated with Crohn’s Disease, Disease Behavior, and Extraintestinal Manifestations in Hungarian PatientsDigestive Diseases and Sciences, 2007